PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21519015-0	2011	Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.	AZD 6244	69-80	mitogen-activated protein kinase 12	Homo sapiens	22-58	
33354735-1	2021	Selumetinib, a highly specific mitogen-activated protein kinase 1/2 inhibitor, is approved for children older than 2 years of age with neurofibromatosis 1 who have inoperable plexiform neurofibromas.	AZD 6244	0-11	mitogen-activated protein kinase 12	Homo sapiens	31-67	
33354735-2	2021	By selectively binding to mitogen-activated protein kinase 1/2 proteins, selumetinib can arrest the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway that regulates critical cellular responses.	AZD 6244	73-84	mitogen-activated protein kinase 12	Homo sapiens	26-62	
27837934-1	2016	PURPOSE: Selumetinib (AZD6244, ARRY-142886) is an oral, potent, and selective allosteric mitogen-activated protein kinase 1/2 inhibitor with a short t1/2.	AZD 6244	9-20	mitogen-activated protein kinase 12	Homo sapiens	89-125	
27837934-1	2016	PURPOSE: Selumetinib (AZD6244, ARRY-142886) is an oral, potent, and selective allosteric mitogen-activated protein kinase 1/2 inhibitor with a short t1/2.	AZD 6244	22-29	mitogen-activated protein kinase 12	Homo sapiens	89-125	
24375836-1	2014	AZD6244, an ATP-uncompetitive inhibitor of mitogen-activated protein kinase 1/2 (MEK1/2), has shown activity in several malignant tumours.	AZD 6244	0-7	mitogen-activated protein kinase 12	Homo sapiens	43-79	
24375836-1	2014	AZD6244, an ATP-uncompetitive inhibitor of mitogen-activated protein kinase 1/2 (MEK1/2), has shown activity in several malignant tumours.	AZD 6244	0-7	mitogen-activated protein kinase 12	Homo sapiens	81-87